This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of scientists from the universities of Glasgow and Tel Aviv has developed a groundbreaking method to transform the brain parasite Toxoplasma gondii into a potential vehicle for delivering therapeutic treatments directly to brain cells.
Genentech’s ocular implant drugdeliverysystem for treatment of macular degeneration has received approval from the US Food and Drug Administration (FDA). Susvimo delivers ranibizumab via a port deliverysystem into a surgically placed implant in the eye, allowing for continuous delivery of the drug.
at Northwestern University—has developed novel technology with the potential to change the future of drugdelivery. A team of scientists—led by Yamin Zhang, Ph.D., and Colin Franz, MD, Ph.D., at Shirley Ryan AbilityLab and John Rogers, Ph.D.,
The purpose of writing this review on floating drugdeliverysystems (FDDS) was to The recent developments of FDDS including the physiological and formulation variables affecting gastric retention, approaches to design single-unit and multiple-unit floating systems, and their classification and formulation aspects are covered in detail.
Ceapro has extended a partnership underway to carry out a further research project with McMaster University for developing an inhalable immuno-therapeutic/-prophylactic for Covid-19-induced lung fibrosis. This project is intended to develop therapies for people suffering from Covid-19’s long-term effects.
Sixfold Bioscience in partnership with Medicines Discovery Catapult, has been given the green light, through the award of an Innovate UK Smart Grant to test a pioneering system designed to deliver drugs directly to cancerous cells, without impacting the healthy cells around it.
Interestingly, over the past few years, drugdevelopers focused on non-respiratory diseases have also shifted their attention towards intranasal drug formulations. This can be attributed to ease of delivery, increased bioavailability and by-pass of first-pass metabolism offered by this type of route of administration.
Furthermore, a wide variety of drugs and macromolecules, including DNA , proteins, and imaging agents, can be encapsulated in liposomal vesicles due to their unique ability to entrap both lipophilic and hydrophilic substances. The various therapeutic applications of liposomes in drugdelivery have been highlighted in the figure.
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drugdelivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drugdelivery.
Liposomes are concentric bilayer vesicles, which were first developed by Bangham and his colleagues in 1961. They are highly efficient having high drug entrapment capacity. Due to their size, hydrophobic and lipophilic character they are most widely used vehicles for drugdelivery. The size range varies from 0.05-5.0µ
CPhI Worldwide will see Gerresheimer showcase its latest developments in primary packaging, drugdeliverysystems for newly developed biologics along with medical and diagnostic products.
In a promising advancement, scientists from the University of North Carolina at Chapel Hill and Emory University have developed a novel drugdeliverysystem using synthetic amyloid beta (AÎ) peptides.
Elyxyb is a prescription nonsteroidal anti-inflammatory drug (NSAID) used for acute migraine treatment in adult patients with or without aura. It is formulated using a self-micro-emulsifying drugdeliverysystem that improves the drug’s bioavailability and solubility.
Decoy-20 is under clinical development by Indaptus Therapeutics and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I drugs for Hepatocellular Carcinoma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. it is administered through intravenous route.
Hydrocortisone is under clinical development by Antares Pharma and currently in Phase I for Adrenal Insufficiency. According to GlobalData, Phase I drugs for Adrenal Insufficiency have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. It is a combination of drug and device.
Scientists have established a new method to image proteins that could lead to new discoveries in disease through biological tissue and cell analysis and the development of new biomaterials that can be used for the next generation of drugdeliverysystems and medical devices.
Hence, a precision therapy or we can say a target therapy (involving intracellular drugdelivery) is much needed to all the patients suffering from cancer. Here is how the intracellular drugdelivery comes into action for majority of the fatal diseases that requires target therapy. The answer is yes. The answer is yes.
The information contained within the download document is intended for pharmaceutical manufacturers, wholesalers, retailers and distributors, pharmaceutical executives, medical representatives, business development managers, retail salesmen, sales managers, pharmacy executives, and any other individual involved in pharmaceutical marketing.
Synairgen’s SNG001 among the many potential treatments and vaccines to be delivered via Aerogen’s aerosol drugdeliverysystem Adds to the thousands of COVID-19 patients already safely and effectively treated with Aerogen’s Solo aerosol drugdeliverysystem in the intensive … Continue reading →
–(BUSINESS WIRE)–Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases as well as sustained-release drugdeliverysystems, announced it has been awarded a $1.0-million million grant to develop a long-term bioerodible birth control implant.
In recent years, liposomes have garnered significant interest of researchers, as well as industry players, owing to their potential in diagnosis and treatment of various diseases, with a focus on delivering drugs and genetic material.
Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drugdelivery strategies to the long-acting drugdelivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases.
However, several drugdelivery devices that enable patients to self-administer their respective medications are now available. Biologics have emerged as a direct consequence of the rapid development that has taken place in the field of life sciences, particularly in cell and molecular biology, over the past few decades.
Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. Oral Protein / Peptide-based Drugs.
SHL Medical is a world-leading solutions provider for advanced drugdeliverysystems with a unified purpose to further enable patient independence. Consequently, pharmaceutical and biotech companies are increasingly looking to provide devices that allow patients to self-administer drugs.
The companies allege Moderna’s vaccine uses their technology for a drug-deliverysystem without permission. Citing The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.
However, research related to metabolites is essential to increase the understanding of molecular level interactions, functions, modifications and regulations in cells, therefore, the field of metabolomics plays a vital role in biomarker discovery for early disease diagnosis and prognosis as well as for drug discovery and development processes.
The six-page statement explains that “Brand drug manufacturers may be harming generic competition through the improper listing of patents in the. Of course, the statute says that only drug formulation, composition, or method of use patents are listable, but FDA has not defined the scope of the “drug” that must be covered by the patent.
In order to promote the use of exosomes in various therapeutic applications including targeted drugdelivery vehicles, engineered exosomes and many more, there are a number of companies that offer services related to the isolation, purification, characterization or quantification of exosomes. Want additional details on the pipeline?
With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically engineered cells that, when implanted in mice, will deliver a biologic drug in response to inflammation. million adults in the United States.
Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.
However, certain biological targets have long eluded drugdevelopment efforts. Likewise, there are several other targets that have not yet been successfully drugged and researchers are making significant efforts to identify novel approaches to target them.
Healthcare Technology commonly known as ‘Healthtech’ is the usage of technology developed to aid all healthcare related activities or any software or tool specifically designed to provide assistance to healthcare professionals, administrators, managers in the most effortless way possible. DrugDevelopment.
The US Food and Drug Administration (FDA) also has concerns about the toxic effects of EtO and thus is continuing to encourage new ways to sterilize medical devices and strategies to mitigate the emission levels of EtO while achieving adequate sterilization.
It is worth mentioning that the first radiopharmaceutical peptide-drug conjugate Luthathera was approved by United States Food and Drug Administration (USFDA) in 2018 for the treatment of gastroenteropancreatic neuroendocrine tumors. It consists of somatostatin-derived peptide and DOTA complexed with radioactive isotope 77 Lu.
According to an analysis of the 2013 Medical Expenditure Panel Survey, one in six US adults reported taking a psychiatric drug at least once in 2013. Global sales of over-the-counter and prescription products related to central nervous system (CNS) disease added up to $86 billion in 2019.
Koblitz — After years of silence from FDA on whether certain patents could be listed in the Orange Book, some manufacturers of drug and device combination products have had a rude awakening lately.
The integration of the blue ocean strategy in healthcare landscape, often known as blue ocean therapy, and its application in medical product development, such as blue ocean medical products, is the silver lining that can revolutionize the industry. This strategy is not a silver bullet; it’s a calculated voyage into uncharted waters.
Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. The production of such drug products requires skilled labor, stringent manufacturing protocols and specialized expertise.
Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].
Clinical trials are the backbone of medical research, paving the way for new treatments, drugs, and therapeutic procedures that can potentially revolutionize healthcare. For instance, if the trial involves a novel drug-deliverysystem, the DSMB might include a pharmaceutical scientist.
Outsourcing offers several benefits to the developers including cost saving opportunities, increased operational efficiencies, expedited time-to-market, access to advanced capabilities and technologies, validated quality control setup, flexibility, risk sharing and, in several cases, regulatory support. Our Social Media Platform. Web: [link].
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content